February 28, 2018 / 2:36 PM / 3 months ago

BRIEF-Can Fite Reports On The Progress Of Its Phase II NASH Study With Drug Candidate Namodenoson

Feb 28 (Reuters) - Can Fite Biopharma Ltd:

* CAN FITE REPORTS ON THE PROGRESS OF ITS PHASE II NASH STUDY WITH DRUG CANDIDATE NAMODENOSON

* CAN FITE BIOPHARMA - ‍ANTICIPATES COMPLETION OF PATIENT ENROLLMENT TOWARD END OF 2018 AND DATA RELEASE IN FIRST HALF OF 2019 FROM PHASE II NASH STUDY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below